Codis is a global Contract Development and Manufacturing Organisation (CDMO) that specialises in commercial-scale spray drying, amorphous solid dispersions (ASD), and particle engineering technologies. Established through the integration of Particle Dynamics in the United States and the former EUROAPI spray drying facility in Haverhill, UK, Codis combines over 30 years of regulatory expertise and manufacturing strength under one brand.

Key Products and Services

Spray Drying Services: Offering both aqueous and solvent-based spray drying to enhance the solubility and bioavailability of pharmaceutical compounds.

Amorphous Solid Dispersions (ASD): Specialising in the development of ASDs to improve the dissolution rates of poorly water-soluble drugs.

Particle Engineering: Providing custom particle design and optimisation to meet specific formulation requirements.

Finished Dose Manufacturing: Capabilities include tablet and capsule production, along with secondary packaging and labelling services.

Analytical and Stability Testing: Comprehensive testing services to ensure product quality and regulatory compliance.

Regulatory Support: Assistance with filings and compliance across multiple international regulatory agencies.

Facilities and Capabilities

Codis operates three Good Manufacturing Practice (GMP)-compliant facilities located in St. Louis, Missouri; Seymour, Indiana; and Haverhill, UK. Together, these sites encompass over 40,000 square metres of manufacturing space and possess a combined spray drying capacity exceeding 5,000 metric tons per year. The Haverhill facility, acquired from EUROAPI in June 2025, brings over 30 years of expertise in spray drying, continuous flow chemistry, and regulatory compliance.

Codis stands as a formidable player in the global CDMO landscape, offering comprehensive services from formulation development to commercial manufacturing. With a strong emphasis on quality, regulatory compliance, and innovative particle engineering, Codis is well-positioned to support pharmaceutical companies in bringing complex therapies to market efficiently and effectively.